| Literature DB >> 26213456 |
Agata Goszczyńska1, Halina Kwiecień1, Karol Fijałkowski2.
Abstract
A series of novelEntities:
Keywords: 2-(2-Formylphenoxy)alkanoic acids; Amines; Antibacterial activities; Esters; Reduction; Reductive amination; Schiff bases
Year: 2015 PMID: 26213456 PMCID: PMC4513202 DOI: 10.1007/s00044-015-1397-6
Source DB: PubMed Journal: Med Chem Res ISSN: 1054-2523 Impact factor: 1.965
Scheme 1Synthesis of Schiff bases from formyl esters 1a–g and aniline (2a) or 4-methoxyaniline (2b)
Synthesis of methyl 2-(4-nitro-2-((phenylimino)methyl)phenoxy)butanoate (3a)
| Entry |
| Solvent (mL) | Reaction time (h) | Yielda (%) | |
|---|---|---|---|---|---|
| 1 | 1/1 | THF | 12 | 24 | 91 |
| 2 | 1/1 | THF/MeOH | 6/6 | 5.5 | 93 |
| 3 | 1/1 | DCE | 8 | 24 | 56 |
| 4 | 1/1 | DCEb | 8 | 24 | 91 |
| 5 | 1/1.5 | DCEb | 8 | 24 | 92 |
| 6 | 1.5/1.5 | DCE/MeOH | 4/4 | 72 | 62 |
| 7 | 1/1 | MeOHb | 6 | 3.5 | 99 |
| 8 | 1/1 | – | – | 24 | 77c |
aYield based on GC analysis of the reaction mixture
bCatalytic amount of acetic acid was added
cReaction was carried out without any solvent
Scheme 2Reduction of Schiff bases 3a–f with STAB into amines 4a–f
Scheme 3Catalytic reduction of Schiff bases 5a and 5c–f
Reduction of Schiff base 3a to amine 4a with STAB
| Entry |
| Solvent (mL) | Reaction temp. | Reaction time (h) | Yielda (%) | |
|---|---|---|---|---|---|---|
| 1 | 1/1.4 | DMFc | 14 | 100 °C | 5 | 21 |
| 2 | 1/1.4 | MeOH | 44 | rt | 3 | 23 |
| 3 | 1/1.4 | MeOH | 44 | reflux | 4 | 27 |
| 4 | 1/1.4 | THF | 20 | reflux | 4 | 65 |
| 5 | 1/1.7 | DCE | 20 | rt | 6 | 86 |
| 6 | 1/1.5 | DCEb | 17 | rt | 4 | 93 |
| 7 | 1/2.0 | DCEb | 17 | rt | 4 | 81 |
| 8 | 1/1.5 | DCEc | 17 | rt | 4 | 84 |
aYield based on GC analysis of reaction mixture
bAdded AcOH (0.1 mL)
cAdded AcOH (0.2 mL)
Catalytic reduction of Schiff bases 3a and 3c–f with hydrogen
|
|
| MeOH (mL) | DME (mL) |
| Yield (%) |
|---|---|---|---|---|---|
|
| 0.31/0.031 | 40 | 10 |
| 85 |
|
| 0.20/0.020 | 35 | 7 |
| 82 |
|
| 0.20/0.020 | 35 | 20 |
| 71 |
|
| 0.36/0.036 | 40 | 10 |
| 84 |
|
| 0.16/0.016 | 35 | 7 |
| 74 |
Synthesis of 4a via the direct reductive amination of methyl 2-(2-formyl-4-nitrophenoxy)butanoate (1a)
|
| Solvent (mL) | Catalyst | Reaction time (h) | Yielda (%) |
|---|---|---|---|---|
| 1/1/1 | THF | – | 50 | 42 |
| 1/1/1.45 | THF | – | 50 | 61 |
| 1/1/1 | DCE | – | 50 | 91 |
| 1/1.5/1.5 | DCE | – | 50 | 98 |
| 1/1/1.5 | DCE | – | 4 | 59 |
| 1/1/1.5 | DCE | – | 24 | 86 |
| 1/1/1.5 | DCE | Amberlyst-15 | 4 | 89 |
| 1/1/1.5 | DCE | AcOH | 4 | 98 |
aYield based on GC analysis
Scheme 4Direct reductive amination of formyl esters 1a–f to 4a–f
Antibacterial activitya of the Schiff bases 3a and 3c–e at 10 mg/mL concentration
| Compound |
|
| ||
|---|---|---|---|---|
| MSSA ATCC 25923 | MRSA ATCC 43300 | MLSB clinical isolate | clinical isolate | |
|
| 13 | 8 | 9 | 10 |
|
| 7 | 7 | 8 | 7 |
|
| 10 | 15 | 12 | – |
|
| 8 | 13 | 13 | 7 |
| ciprofloxacin | 25 | 26 | 27 | 28 |
aZone of inhibition in mm; ‘–’ means not sensitive (no antimicrobial activity was recorded)
Minimum inhibitory concentration (MIC, mg/mL) of Schiff bases 3a, c–e
| Compound |
|
| ||
|---|---|---|---|---|
| MSSA ATCC 25923 | MRSA ATCC 43300 | MLSB clinical isolate | clinical isolate | |
|
| 0.10 | 0.10 | 0.10 | 0.50 |
|
| 0.50 | 0.25 | 0.25 | 0.50 |
|
| 0.25 | 0.25 | 0.25 | 1.00 |
|
| 0.25 | 0.10 | 0.10 | 1.00 |
Antibacterial activitya of amino esters 4a–f at 10 mg/mL concentration
| Compound |
|
|
|
| ||
|---|---|---|---|---|---|---|
| ATCC 29212 | MSSA ATCC 25923 | MRSA ATCC 43300 | MLSB clinical isolate | PCM 1944 | clinical isolate | |
|
| 12 | 8 | – | 8 | 15 | 11 |
|
| 12 | 12 | 7 | 7 | 14 | 14 |
|
| 17 | 16 | 13 | 8 | 17 | 21 |
|
| 8 | – | – | – | 8 | – |
|
| 13 | 13 | 14 | 12 | 15 | 15 |
| ciprofloxacin | 20 | 25 | 26 | 27 | 22 | 28 |
aZone of inhibition in mm; ‘–’ no antimicrobial activity was recorded
Minimum inhibitory concentration (MIC, mg/mL) of hydrochloride salts of the amino esters 4a–f
| Gram-positive | ||||||
|---|---|---|---|---|---|---|
|
|
|
|
| |||
| ATCC 29212 | MSSA ATCC 25923 | MRSA ATCC 43300 | MLSB clinical isolate | PCM 1944 | clinical isolate | |
|
| 0.50 | 0.50 | NT | 1.00 | 0.50 | 0.50 |
|
| 0.25 | 0.10 | 0.50 | 1.00 | 0.05 | 0.25 |
|
| 0.05 | 0.10 | 0.25 | 0.50 | 0.05 | 0.10 |
|
| 0.50 | NT | NT | NT | 1.00 | NT |
|
| 0.05 | 0.01 | 0.25 | 0.25 | 0.05 | 0.10 |
NT means not tested
Fig. 1Numbering for 13C NMR spectra